Carter-Wallace DESI hearings
Executive Summary
FDA on June 5 granted firm's request to hold a hearing on an agency proposal to withdraw the NDA for the antihypertensive Diutensen (cryptenamine with methyclothiazide). A prehearing conference has been scheduled for Sept. 25. Also on June 5, FDA agreed to hold a similar hearing on the antidepressant Deprol (meprobamate with benactyzine). A prehearing conference date has not yet been set.